You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences Announces Start of Expanded Access Program for PREVEON®
Oral Influenza Compound Reduced Symptoms and Prevented Illness in Humans
Hoffmann-La Roche and Gilead Sciences Start Phase II Human Testing of Oral Influenza Drug GS 4104
Gilead Sciences Begins Human Testing of Oral PMPA for Treatment of HIV
Gilead Announces Phase I/II Data Insufficient for Marketing Clearance of FORVADETM Topical Gel to Treat Refractory Herpes in Patients with AIDS
Gilead Sciences Receives Marketing Authorization for VISTIDE® in European Union
Gilead's PMPA Significantly Reduces HIV Levels in Phase I/II Study
Gilead Begins Phase II Clinical Trials of Oral GS 840 for Chronic Hepatitis B
Hoffmann-La Roche and Gilead Sciences Initiate Human Testing of Oral Influenza Drug GS 4104
Donald H. Rumsfeld Named Chairman of Gilead Sciences
2012 Interactive Annual Report